Skip to main content
Journal cover image

Polymorphisms in NF-kappaB inhibitors and risk of epithelial ovarian cancer.

Publication ,  Journal Article
White, KL; Vierkant, RA; Phelan, CM; Fridley, BL; Anderson, S; Knutson, KL; Schildkraut, JM; Cunningham, JM; Kelemen, LE; Pankratz, VS ...
Published in: BMC Cancer
June 6, 2009

BACKGROUND: The nuclear factor-kappaB (NF-kappaB) family is a set of transcription factors with key roles in the induction of the inflammatory response and may be the link between inflammation and cancer development. This pathway has been shown to influence ovarian epithelial tissue repair. Inhibitors of kappaB (IkappaB) prevent NF-kappaB activation by sequestering NF-kappaB proteins in the cytoplasm until IkappaB proteins are phosphorylated and degraded. METHODS: We used a case-control study to evaluate the association between single nucleotide polymorphisms (SNPs) in NFKBIA and NFKBIB (the genes encoding IkappaBalpha and IkappaBbeta, respectively) and risk of epithelial ovarian cancer. We queried 19 tagSNPs and putative-functional SNPs among 930 epithelial ovarian cancer cases and 1,037 controls from two studies. RESULTS: The minor allele for one synonymous SNP in NFKBIA, rs1957106, was associated with decreased risk (p = 0.03). CONCLUSION: Considering the number of single-SNP tests performed and null gene-level results, we conclude that NFKBIA and NFKBIB are not likely to harbor ovarian cancer risk alleles. Due to its biological significance in ovarian cancer, additional genes encoding NF-kappaB subunits, activating and inhibiting molecules, and signaling molecules warrant interrogation.

Duke Scholars

Published In

BMC Cancer

DOI

EISSN

1471-2407

Publication Date

June 6, 2009

Volume

9

Start / End Page

170

Location

England

Related Subject Headings

  • Young Adult
  • Polymorphism, Single Nucleotide
  • Ovarian Neoplasms
  • Oncology & Carcinogenesis
  • NF-KappaB Inhibitor alpha
  • Middle Aged
  • Linkage Disequilibrium
  • I-kappa B Proteins
  • Humans
  • Haplotypes
 

Citation

APA
Chicago
ICMJE
MLA
NLM
White, K. L., Vierkant, R. A., Phelan, C. M., Fridley, B. L., Anderson, S., Knutson, K. L., … Goode, E. L. (2009). Polymorphisms in NF-kappaB inhibitors and risk of epithelial ovarian cancer. BMC Cancer, 9, 170. https://doi.org/10.1186/1471-2407-9-170
White, Kristin L., Robert A. Vierkant, Catherine M. Phelan, Brooke L. Fridley, Stephanie Anderson, Keith L. Knutson, Joellen M. Schildkraut, et al. “Polymorphisms in NF-kappaB inhibitors and risk of epithelial ovarian cancer.BMC Cancer 9 (June 6, 2009): 170. https://doi.org/10.1186/1471-2407-9-170.
White KL, Vierkant RA, Phelan CM, Fridley BL, Anderson S, Knutson KL, et al. Polymorphisms in NF-kappaB inhibitors and risk of epithelial ovarian cancer. BMC Cancer. 2009 Jun 6;9:170.
White, Kristin L., et al. “Polymorphisms in NF-kappaB inhibitors and risk of epithelial ovarian cancer.BMC Cancer, vol. 9, June 2009, p. 170. Pubmed, doi:10.1186/1471-2407-9-170.
White KL, Vierkant RA, Phelan CM, Fridley BL, Anderson S, Knutson KL, Schildkraut JM, Cunningham JM, Kelemen LE, Pankratz VS, Rider DN, Liebow M, Hartmann LC, Sellers TA, Goode EL. Polymorphisms in NF-kappaB inhibitors and risk of epithelial ovarian cancer. BMC Cancer. 2009 Jun 6;9:170.
Journal cover image

Published In

BMC Cancer

DOI

EISSN

1471-2407

Publication Date

June 6, 2009

Volume

9

Start / End Page

170

Location

England

Related Subject Headings

  • Young Adult
  • Polymorphism, Single Nucleotide
  • Ovarian Neoplasms
  • Oncology & Carcinogenesis
  • NF-KappaB Inhibitor alpha
  • Middle Aged
  • Linkage Disequilibrium
  • I-kappa B Proteins
  • Humans
  • Haplotypes